Keywords
DOI:
https://doi.org/10.17566/ciads.v8i4.572How to Cite
Abstract
Objective: to describe the regulatory aspects of larotrectinib, the first approved drug with indication for tumor-agnosis in Brazil, and its likely impacts on judicialization in the country. Methods: this is a descriptive exploratory study. Results and discussion: larotrectinib was approved in Brazil about 225 days after FDA approval. Its approval brings new elements to the discussion of judicialization in health, since few patients will benefit from this therapy. The prevalence of fusion of the NTRK receptor (larotrectinib target mutation) gene is known to be 0.31% of adult tumors and 0.34% of pediatric patient tumors. In addition, pharmacogenetic tests are required to confirm this mutation. Conclusion: with the registration of drugs with tumor-agnostic indication becoming a reality in Brazil, the need for presentation and interpretation of pharmacogenetic tests is increasing. However, this is not a reality in the Unified Health System and, therefore, these drugs tend to benefit only those who have access to pharmacogenetic tests, have the specific mutation for treatment, thus promoting legal demands and thus restricting their access to large majority of the population.
References
Sidaway P. Larotrectinib effective against TRK-fusion-positive cancers. Nat Rev Clin Oncol [Internet]. 2018 May 13;15(5):264–264. Disponível em: http://www.nature.com/articles/nrclinonc.2018.40
Offin M, Liu D, Drilon A. Tumor-Agnostic Drug Development. Am Soc Clin Oncol Educ B [Internet]. 2018 May 23;(38):184–7. Disponível em: https://doi.org/10.1200/EDBK_200831
U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. [Internet]. 2018 [Acesso em 02 agosto 2019]. Disponível em: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
Lacombe D, Burock S, Bogaerts J, Schoeffski P, Golfinopoulos V, Stupp R. The dream and reality of histology agnostic cancer clinical trials. Mol Oncol [Internet]. 2014 Sep 12;8(6):1057–63. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25349876
Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, et al. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. J Clin Oncol [Internet]. 2017;35(3):271–3. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/27893325
Chen C, Li X (Nicole), Yuan S, Antonijevic Z, Kalamegham R, Beckman RA. Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study. Stat Biopharm Res [Internet]. 2016 Jul 2;8(3):248–57. Disponível em: https://www.tandfonline.com/doi/full/10.1080/19466315.2016.1193044
Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, et al. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv [Internet]. 2019 Jul 23;3(14):2237–43. Disponível em: http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvances.2019031229
Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, et al. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol [Internet]. 2017 Nov 1;(1):1–5. Disponível em: https://doi.org/10.1200/PO.17.00181
Chen AP, Eljanne M, Harris L, Malik S, Seibel NL. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond. Cancer J [Internet]. 25(4):272–81. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/31335391
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med [Internet]. 2018;378(8):731–9. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29466156
U.S. Food and Drug Administration. Fast Track [Internet]. [Acesso em 29 Jul 2019]. Disponível em: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, et al. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. J Clin Oncol [Internet]. 2018;36(18):1805–12. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29688832
Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA [Internet]. 2017 Aug 15;318(7):626–36. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/28810023
Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, et al. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ [Internet]. 2018;361:k2031. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29794072
Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med [Internet]. 2019 May 28; Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/31135822
Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med [Internet]. 2019 Jul 1;179(7):906. Disponível em: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2019.0462
Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials [Internet]. 2016;13(3):358–66. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/26908536
Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med [Internet]. 2017;377(1):62–70. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/28679092
Berry DA. The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol [Internet]. 2015 May;9(5):951–9. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25888066
Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol [Internet]. 2015 May;9(5):967–96. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/25557400
Yan L, Zhang W. Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun (London, England) [Internet]. 2018;38(1):6. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/29764494
Le Tourneau C, Kamal M, Bièche I. Precision medicine in oncology: what is it exactly and where are we? Per Med [Internet]. 2018 Sep;15(5):351–3. Disponível em: https://www.futuremedicine.com/doi/10.2217/pme-2018-0036
Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov [Internet]. 2018 Feb;8(2):174–83. Disponível em: http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-17-0321
Buljan M, Blattmann P, Aebersold R, Boutros M. Systematic characterization of pan‐cancer mutation clusters. Mol Syst Biol [Internet]. 2018 Mar 23;14(3):e7974. Disponível em: http://msb.embopress.org/lookup/doi/10.15252/msb.20177974
Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U. Hotspot mutations in cancer genes may be missed in routine diagnostics due to neighbouring sequence variants. Exp Mol Pathol [Internet]. 2018 Aug;105(1):37–40. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0014480018301734
Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol [Internet]. 2016 Feb;34(2):155–63. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/26619011
Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol [Internet]. 2018 Nov;2(1):1–20. Disponível em: http://ascopubs.org/doi/10.1200/PO.18.00183
Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, et al. Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. J Oncol Pract [Internet]. 2018 Oct 24;JOP1800120. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/30355027
Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med [Internet]. 2018 May;6(9):166–166. Disponível em: http://atm.amegroups.com/article/view/19114/19491
World Health Organization. Pricing of cancer medicines and its impacts [Internet]. 2018. [Acesso em 29 Jul 2019]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf
Bayer. TRAK AssistTM [Internet]. [Acesso em 29 Jul 2019]. Disponível em: https://www.hcp.vitrakvi-us.com/access/
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 CADERNOS IBERO-AMERICANOS DE DIREITO SANITÁRIO